Last reviewed · How we verify
Vivitrol Injectable Product
At a glance
| Generic name | Vivitrol Injectable Product |
|---|---|
| Sponsor | Inventage Lab., Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions (NA)
- Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses (PHASE4)
- iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers (PHASE1)
- Promoting Alcohol Treatment Engagement Post-hospitalization (NA)
- Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail (PHASE2, PHASE3)
- Naltrexone in AUD Reward Drinkers (PHASE4)
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America (PHASE4)
- Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vivitrol Injectable Product CI brief — competitive landscape report
- Vivitrol Injectable Product updates RSS · CI watch RSS
- Inventage Lab., Inc. portfolio CI